CASE COMMENTS : PHASE I – CONDITIONAL CLEARANCE – MEDICAL TECHNOLOGY

Phase I - Conditional clearance : The European Commission conditionally clears an acquisition by a healthcare company of a medical technology company (Baxter / Gambro)

*This article is an automatic translation of the original article, provided here for your convenience. Read the original article. This is not the first time that the medical sector has been the subject of consolidation and attention by the Commission (to name but a few, see Commission Decisions of 5 October 2011 in Case COMP/M.6091 - Galenica / Fresenius Medical Care / Vifor Fresenius Medical Care Renal Pharma JV or of 8 December 2005, Case COMP/M.4010 - Fresenius / Helios or of 4 October 2001, Case COMP/M.2505 - Tyco / CR Bard). This time it was a question of the US company Baxter International Inc (hereinafter Baxter) acquiring sole control of the Swedish company Gambro AB (hereinafter Gambro). On 4 December 2012 it concluded an agreement whereby it acquired from Indap Sweden AB

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

  • University Paris II Panthéon‑Assas

Quotation

Dominique Berlin, Phase I - Conditional clearance : The European Commission conditionally clears an acquisition by a healthcare company of a medical technology company (Baxter / Gambro), 22 September 2013, Concurrences N° 1-2014, Art. N° 62673, pp. 126-129

Visites 170

All reviews